Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hutchison MediPharma Inks $140 Million Cancer Deal with AstraZeneca

publication date: Dec 21, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma announced a new partnership with AstraZeneca that will jointly develop a pre-clinical cancer molecule, volitinib (HMPL-504). Volitinib is a novel inhibitor of the c-Met receptor tyrosine kinase. According to HMP, the drug candidate will soon begin a Phase I trial. AstraZeneca made a $20 million upfront payment, and the agreement calls for up to $120 million in milestones. More details....

Stock Symbol: (NYSE: AZN)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners